FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079306975> ?p ?o ?g. }

• W2079306975 endingPage "492" @default.
• W2079306975 startingPage "486" @default.
• W2079306975 abstract "Progression of renal failure, despite renoprotection with angiotensin-converting enzyme (ACE) inhibitors in patients with proteinuric nephropathies, may be caused by persistent renal production of transforming growth factor-beta1 (TGF-beta1) through the angiotensin II subtype 1 (AT1) receptors. We tested the hypothesis that AT1-receptor blocker therapy added to a background of chronic maximal ACE inhibitor therapy will result in a reduction in urinary TGF-beta1 levels in such patients. Sixteen patients completed a two-period, crossover, randomized, controlled trial, details of which have been previously reported. All patients were administered lisinopril, 40 mg/d, with either losartan, 50 mg/d, or placebo. Blood pressure (BP) was measured using a 24-hour ambulatory BP monitor. Overnight specimens of urine were analyzed for urine TGF-beta1, protein, and creatinine concentrations. Mean age of the study population was 53 +/- 9 (SD) years; body mass index, 38 +/- 5.7 kg/m2; seated BP, 156 +/- 18/88 +/- 12 mm Hg; and urine protein excretion, 3.6 +/- 0.71 g/g of creatinine. Twelve patients had diabetic nephropathy, and the remainder had chronic glomerulonephritis. At baseline, urinary TGF-beta1 levels were significantly increased in the study population compared with healthy controls (13.2 +/- 1.2 versus 1.7 +/- 1.1 ng/g creatinine; P < 0.001). There was a strong correlation between baseline urine protein excretion and urinary TGF-beta1 level (r2 = 0.53; P = 0.001), as well as systolic BP and urinary TGF-beta1 level (r2 = 0.57; P < 0.001). After 4 weeks of add-on losartan therapy, there was a 38% (95% confidence interval [CI], 16% to 55%) decline in urinary TGF-beta1 levels (13.3 [95% CI, 11.4 to 15.5] to 8.2 pg/mg creatinine [95% CI, 6.2 to 10.7]). The reduction in urinary TGF-beta1 levels occurred independent of changes in mean urinary protein excretion or BP. Thus, proteinuric patients with renal failure, despite maximal ACE inhibition, had increased urinary levels of TGF-beta1 that improved over 1 month of add-on therapy with losartan. We speculate that dual blockade with losartan and an ACE inhibitor may provide additional renoprotection by decreasing renal production of TGF-beta1." @default.
• W2079306975 created "2016-06-24" @default.
• W2079306975 creator A5050951131 @default.
• W2079306975 creator A5051708137 @default.
• W2079306975 creator A5087355911 @default.
• W2079306975 creator A5088903449 @default.
• W2079306975 date "2002-03-01" @default.
• W2079306975 modified "2023-09-25" @default.
• W2079306975 title "Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels" @default.
• W2079306975 cites W1521804991 @default.
• W2079306975 cites W1971823155 @default.
• W2079306975 cites W1984261234 @default.
• W2079306975 cites W2005720719 @default.
• W2079306975 cites W2018312583 @default.
• W2079306975 cites W2047789886 @default.
• W2079306975 cites W2059309249 @default.
• W2079306975 cites W2060832611 @default.
• W2079306975 cites W2061202476 @default.
• W2079306975 cites W2066538838 @default.
• W2079306975 cites W2074563683 @default.
• W2079306975 cites W2075391935 @default.
• W2079306975 cites W2077619917 @default.
• W2079306975 cites W2083008696 @default.
• W2079306975 cites W2107545715 @default.
• W2079306975 cites W2108807575 @default.
• W2079306975 cites W2108910108 @default.
• W2079306975 cites W2116613369 @default.
• W2079306975 cites W2125862902 @default.
• W2079306975 cites W2145529099 @default.
• W2079306975 cites W2156379999 @default.
• W2079306975 cites W2165325650 @default.
• W2079306975 cites W2171083892 @default.
• W2079306975 cites W2183670426 @default.
• W2079306975 cites W2297148142 @default.
• W2079306975 cites W2321986725 @default.
• W2079306975 cites W2323072331 @default.
• W2079306975 cites W2394914616 @default.
• W2079306975 cites W3156148333 @default.
• W2079306975 cites W4322702037 @default.
• W2079306975 doi "https://doi.org/10.1053/ajkd.2002.31392" @default.
• W2079306975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11877567" @default.
• W2079306975 hasPublicationYear "2002" @default.
• W2079306975 type Work @default.
• W2079306975 sameAs 2079306975 @default.
• W2079306975 citedByCount "104" @default.
• W2079306975 countsByYear W20793069752012 @default.
• W2079306975 countsByYear W20793069752013 @default.
• W2079306975 countsByYear W20793069752014 @default.
• W2079306975 countsByYear W20793069752015 @default.
• W2079306975 countsByYear W20793069752016 @default.
• W2079306975 countsByYear W20793069752018 @default.
• W2079306975 countsByYear W20793069752020 @default.
• W2079306975 countsByYear W20793069752021 @default.
• W2079306975 countsByYear W20793069752022 @default.
• W2079306975 countsByYear W20793069752023 @default.
• W2079306975 crossrefType "journal-article" @default.
• W2079306975 hasAuthorship W2079306975A5050951131 @default.
• W2079306975 hasAuthorship W2079306975A5051708137 @default.
• W2079306975 hasAuthorship W2079306975A5087355911 @default.
• W2079306975 hasAuthorship W2079306975A5088903449 @default.
• W2079306975 hasConcept C126322002 @default.
• W2079306975 hasConcept C126894567 @default.
• W2079306975 hasConcept C134018914 @default.
• W2079306975 hasConcept C159641895 @default.
• W2079306975 hasConcept C27016395 @default.
• W2079306975 hasConcept C2779611605 @default.
• W2079306975 hasConcept C2780288358 @default.
• W2079306975 hasConcept C2780306776 @default.
• W2079306975 hasConcept C2908647359 @default.
• W2079306975 hasConcept C2908929049 @default.
• W2079306975 hasConcept C71924100 @default.
• W2079306975 hasConcept C77411442 @default.
• W2079306975 hasConcept C84393581 @default.
• W2079306975 hasConcept C99454951 @default.
• W2079306975 hasConceptScore W2079306975C126322002 @default.
• W2079306975 hasConceptScore W2079306975C126894567 @default.
• W2079306975 hasConceptScore W2079306975C134018914 @default.
• W2079306975 hasConceptScore W2079306975C159641895 @default.
• W2079306975 hasConceptScore W2079306975C27016395 @default.
• W2079306975 hasConceptScore W2079306975C2779611605 @default.
• W2079306975 hasConceptScore W2079306975C2780288358 @default.
• W2079306975 hasConceptScore W2079306975C2780306776 @default.
• W2079306975 hasConceptScore W2079306975C2908647359 @default.
• W2079306975 hasConceptScore W2079306975C2908929049 @default.
• W2079306975 hasConceptScore W2079306975C71924100 @default.
• W2079306975 hasConceptScore W2079306975C77411442 @default.
• W2079306975 hasConceptScore W2079306975C84393581 @default.
• W2079306975 hasConceptScore W2079306975C99454951 @default.
• W2079306975 hasIssue "3" @default.
• W2079306975 hasLocation W20793069751 @default.
• W2079306975 hasLocation W20793069752 @default.
• W2079306975 hasOpenAccess W2079306975 @default.
• W2079306975 hasPrimaryLocation W20793069751 @default.
• W2079306975 hasRelatedWork W1546532984 @default.
• W2079306975 hasRelatedWork W1562186448 @default.
• W2079306975 hasRelatedWork W1966732677 @default.
• W2079306975 hasRelatedWork W1998254130 @default.
• W2079306975 hasRelatedWork W2027470168 @default.

• next